Core Viewpoint - LB Pharmaceuticals has appointed Ellen Rose and Lindsay Beaupre to key executive positions, aiming to enhance corporate affairs and organizational culture as the company advances its lead product candidate, LB-102, for neuropsychiatric diseases [1][2][3] Group 1: Executive Appointments - Ellen Rose has been appointed as Senior Vice President, Corporate Affairs, bringing extensive experience in corporate communications, investor relations, and patient advocacy from her previous roles at Lyell Immunopharma and Prothena Corporation [2][3] - Lindsay Beaupre has been appointed as Senior Vice President, People and Culture, with a strong background in organizational effectiveness and leadership from her tenure at Lyndra Therapeutics and other biotech firms [2][3] Group 2: Product Development - LB-102 is a Phase 3-ready oral small molecule, a methylated derivative of amisulpride, currently advancing into pivotal development for schizophrenia and a Phase 2 trial for bipolar depression [4][5] - Positive data from a Phase 2 trial in early 2025 showed statistically significant benefits versus placebo, indicating a potentially class-leading safety profile and positive effects on negative symptoms and cognition [4][5] Group 3: Market Potential - If approved, LB-102 could become a mainstay in psychiatric practice, offering an attractive alternative to existing treatments for schizophrenia and bipolar depression [6] - The company is exploring additional indications for LB-102, including major depressive disorder, Alzheimer's disease psychosis, and cognitive impairment associated with schizophrenia [4][5]

Core Insights - LB Pharmaceuticals Inc will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 9:30 a.m. ET [1] - A live webcast of the presentation will be available on the Company's website [2] Product Development - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing statistically significant benefits in a Phase 2 trial for acute schizophrenia [3] - The Phase 2 trial demonstrated a potentially class-leading safety profile among D2 antagonists and partial agonists, with positive effects on negative symptoms and cognition [3] - LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression, with potential expansion into major depressive disorder, Alzheimer's disease psychosis, and other conditions [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The Company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 has the potential to be a mainstay in psychiatric practice, offering an attractive alternative to existing treatments [4]

Core Insights - LB Pharmaceuticals Inc will present at the Stifel 2025 Healthcare Conference on November 13, 2025, at 9:20 a.m. ET [1] - A live webcast of the presentation will be available on the Company's website [2] Product Development - LB-102 is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, showing positive results in a Phase 2 trial for acute schizophrenia [3] - The Phase 2 trial demonstrated statistically significant benefits versus placebo at all doses, a potentially leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition [3] - LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 trial for bipolar depression, with potential expansion into major depressive disorder, Alzheimer's disease psychosis, and other conditions [3] Company Overview - LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [4] - The Company aims to leverage the therapeutic potential of LB-102, which could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the U.S. [4] - If approved, LB-102 has the potential to be a mainstay in psychiatric practice, offering an attractive alternative to existing treatments [4]